基因检测
医学
生物标志物
痴呆
载脂蛋白E
疾病
临床试验
知情同意
淀粉样蛋白(真菌学)
重症监护医学
生物信息学
肿瘤科
内科学
病理
替代医学
遗传学
生物
作者
Marina Ritchie,S. Ahmad Sajjadi,Joshua D. Grill
出处
期刊:Neurology
[Lippincott Williams & Wilkins]
日期:2024-01-05
卷期号:14 (2): e200230-e200230
被引量:38
标识
DOI:10.1212/cpj.0000000000200230
摘要
The recent FDA approval of amyloid-lowering drugs is changing the landscape of Alzheimer disease (AD) clinical practice. Previously, apolipoprotein E (APOE) genetic testing was not recommended in the care of people with AD because of limited clinical utility. With the advent of amyloid-lowering drugs, APOE genotype will play an important role in guiding treatment recommendations. Recent clinical trials have reported strong associations between APOE genotype and the safety and possibly the efficacy of amyloid-lowering drugs. Therefore, a clinical workflow that includes biomarker and genetic testing should be implemented to provide patients with the opportunity to make informed decisions and instruct safety monitoring for clinicians. Pretest consent, education, and counseling will be an essential aspect of this process for patients and their family members to understand the implications of these tests and their results. Given that the approved amyloid-lowering drugs are indicated for patients with mild cognitive impairment or mild dementia with biomarker evidence of AD, biomarker testing should be performed before genetic testing and genetic testing should only be performed in patients interested in treatment with amyloid-lowering drugs. It is also important to consider other implications of genetic testing, including burden on and need for additional training for clinicians, the role of additional providers, and the potential challenges for patients and families.
科研通智能强力驱动
Strongly Powered by AbleSci AI